A CGRP receptor antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Vazegepant (hydrochloride)

Item No. 46217

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-(1,2-dihydro-2-oxo-3-quinolinyl)-N-[(1R)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-1-piperidinecarboxamide, monohydrochloride
CAS Number
1414976-20-7
Synonyms
  • BHV 3500
  • BMS-742413
  • Zavegepant
Molecular Formula
C36H46N8O3 • HCl
Formula Weight
675.3
Purity
≥98%
Formulation (Request formulation change)
A solid
SMILES
O=C(N1CCC(C2=CC3=CC=CC=C3NC2=O)CC1)N[C@H](CC4=CC(C)=C5NN=CC5=C4)C(N6CCN(CC6)C7CCN(CC7)C)=O.Cl
InChi Code
InChI=1S/C36H46N8O3.ClH/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45;/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47);1H/t32-;/m1./s1
InChi Key
VQDUWCSSPSOSNA-RYWNGCACSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $189

    Add

    10 mg

    $284

    Add

    25 mg

    $473

    Add

    50 mg

    $662

    Add
    Product Description

    Vazegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist (Ki = 23 pM in SK-N-MC membrane preparations).1 It is >10,000-fold selective for the CGRP receptor over the adrenomedullin receptor 1 (AM1 receptor), AM2 receptor, calcitonin (CT) receptor, amylin 1 (AMY1) receptor, and AMY3 receptor. Ex vivo, vazegepant reverses CGRP-induced dilation of human intracranial arteries (EC50 = 880 pM) but does not induce contractions in human coronary arteries when used at concentrations up to 10 µM. It reduces human α-CGRP-induced increases in facial blood flow in marmosets when administered subcutaneously at a dose of 0.03 mg/kg. Formulations containing vazegepant have been used in the treatment of migraines.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Chaturvedula, P.V., Mercer, S.E., Pin, S.S., et al. Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): A potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery. Bioorg. Med. Chem. Lett. 23(11), 3157-3161 (2013).